Register update: there will be a delay adding new records during our holiday period (Dec 17 - Jan 4)
Cochrane COVID-19 Study Register
Study record
Song 2020kFirst Published: 2020 Jul 4Updated Date: 2020 Aug 14

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis

  1. Study Type
  2. Observational
  1. Study Aim
  2. Diagnostic/Prognostic
  3. Mechanism
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
Reference record

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis

Song JW, Lam SM, Fan X, Cao WJ, Wang SY, Tian H, Chua GH, Zhang C, Meng FP, Xu Z, Fu JL, Huang L, Xia P, Yang T, Zhang S, Li B, Jiang TJ, Wang R, Wang Z, Shi M, Zhang JY, Wang FS, Shui G
Journal article
Report Results
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented threat to global public health. Herein, we utilized a combination of targeted and untargeted tandem mass spectrometry to analyze the plasma lipidome and metabolome in mild, moderate, and severe COVID-19 patients and healthy controls. A panel of 10 plasma metabolites effectively distinguished COVID-19 patients from healthy controls (AUC = 0.975). Plasma lipidome of COVID-19 resembled that of monosialodihexosyl ganglioside (GM3)-enriched exosomes, with enhanced levels of sphingomyelins (SMs) and GM3s, and reduced diacylglycerols (DAGs). Systems evaluation of metabolic dysregulation in COVID-19 was performed using multiscale embedded differential correlation network analyses. Using exosomes isolated from the same cohort, we demonstrated that exosomes of COVID-19 patients with elevating disease severity were increasingly enriched in GM3s. Our work suggests that GM3-enriched exosomes may partake in pathological processes related to COVID-19 pathogenesis and presents the largest repository on the plasma lipidome and metabolome distinct to COVID-19